Anti-Human IL-17RA (CD217) (Brodalumab) (I-2120-50mg)

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer1. IL-17 signaling is also critical for protection against fungal and bacterial infection2. There are six pro-inflammatory cytokines (IL-17A-F) produced by Th17 cells, and the IL-17RA receptor is used by IL-17A, IL-17C, IL- 17E, and IL-17F to promote signaling and downstream responses3. IL-17RA binds IL-17 with coreceptor IL-17RC to initiate signaling events1,2. Blocking the IL-17RA receptor prevents the release of IL-17-mediated proinflammatory protein kinases and chemokines3. IL-17 and IL- 17RA blockade have therefore been explored as immunotherapy for various autoimmune diseases. Brodalumab binds with high affinity to human IL-17RA and blocks signaling of IL-17A, F, and A/F heterodimer via the IL-17RA/RC complex as well as IL-17E signaling via the IL-17RA/RB complex 4,5 4,5. Brodalumab is approved to treat moderate to severe plaque psoriasis but was found to make Crohn’s disease worse3. Brodalumab is also known as AMG 827/KHK 48276.